TY  - JOUR
UR  - https://doi.org/10.1007/s40266-018-0590-y
SN  - 1179-1969
JF  - Drugs and Aging
A1  - Estevez-Fraga, C
A1  - Zeun, P
A1  - Lopez-Sendon Moreno, JL
VL  - 35
SP  - 959
IS  - 11
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
N2  - Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are iatrogenic consequences of antidopaminergic drugs. Both are particularly prevalent among the elderly and those with dementia. However, despite their prevalence, these disorders are often overlooked. Both entities share risk factors, physiopathological mechanisms and, to some degree, therapeutic approaches. Withdrawing the causal agent, reducing the dose or switching to a less potent antidopaminergic drug should be the first therapeutic options. Here we review both entities and emerging therapies including the recently approved drugs deutetrabenazine and valbenazine. We discuss relevant aspects for clinical practice such as new diagnostic techniques and the latest advances in the understanding of DIP and TD.
ID  - discovery10062802
PB  - ADIS INT LTD
TI  - Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly
AV  - public
Y1  - 2018/11//
EP  - 971
ER  -